Sutro Biopharma, Inc. · NASDAQ:STRO

Sutro Biopharma — Investor Presentation (November 2022)

31 slides from Sutro Biopharma's investor presentation, November 2022

  1. Slide 1: Company Overview

    Company Overview November 2022 Sutro Biopharma NASDAQ: STRO 1 NON-CONFIDENTIAL

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state

  3. Slide 3: Sutro is a Clinical-Stage Oncology Company Pioneering Next-Generation Novel Format ADCs

    Sutro is a Clinical-Stage Oncology Company Pioneering Next-Generation Novel Format ADCs that are Site-Specific STRO-002 Platform Phase 1 data show encouraging Platform enabled the first bispecific efficacy across a wide range of ADC in the clinic and allows for the ovarian cancer patients with novel

  4. Slide 4: Six Product Candidates in Clinical Development are Enabled by Sutro's Platform

    Six Product Candidates in Clinical Development are Enabled by Sutro’s Platform Unique engineering prowess in the field of precisely conjugated biologics, including next-gen ADCs Modality Program Target(s) Indication Discovery Preclinical Phase 1/1b Phase 2/3 Partner Ovarian Cancer Fast Track Designa

  5. Slide 5: Achievements and Milestones

    Achievements and Milestones Clinical data readouts and partnerships provide multiple anticipated 2022 value drivers for Sutro STRO-002, FolRα ADC STRO-001, CD74 ADC ✓ • Greater China deal with Tasly (Dec. 2021) ✓ • BioNova submission of IND to the NMPA for the treatment of hematological malignancies

  6. Slide 6: STRO-002 FolRα-Targeting ADC

    STRO-002 FolRα-Targeting ADC 6 NON-CONFIDENTIAL

  7. Slide 7: Highly Optimized ADC Designed to Drive Efficient Tumor Responses across a Broad Range of Target Antigen Levels

    STRO 002 Highly Optimized ADC Designed to Drive Efficient Tumor Responses across a Broad Range of Target Antigen Levels 1 FolRα STRO-002 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 4, targeting folate-receptor alpha (FolRα) Y180 1 FolRα is overexpressed in cert

  8. Slide 8: Phase 1 Study in Patients with Advanced Ovarian Cancer

    Phase 1 Study in Patients with Advanced Ovarian Cancer STRO 002 Two-part design to explore safety, anti-tumor activity, dosing, and FolRα enrichment strategy Part 1: Dose-Escalation Cohort Part 2: Dose-Expansion Cohort Protocol Inclusive of all FolRα expression levels; tissue samples Inclusive of al

  9. Slide 9: Patient Characteristics in Dose Expansion Cohort

    Patient Characteristics in Dose Expansion Cohort STRO 002 Dose Expansion Interim data for dose expansion as of November 8, 2021 Patient Baseline Characteristics Patient Status as of November 8, 2021 Randomized Dose Levels Total Patients Enrolled Total N=44 Ovarian Cancer 4.3 mg/kg 5.2 mg/kg N=43 Pat

  10. Slide 10: Dose Response Demonstrated

    Dose Response Demonstrated STRO 002 Dose Expansion Interim data suggest that 5.2 mg/kg starting dose leads to higher response rates Maximum Change in Tumor Target Lesions (N=33) 20% PRu* PRu PRu* PR PR PR PR PRu* PRu* PR PR PR 2 pts had 0% Δ Partial Response -30% Treatment ongoing Starting Dose, Q3W

  11. Slide 11: Objective Response by RECIST v1.1

    Objective Response by RECIST v1.1 STRO 002 Dose Expansion 33% ORR rate in all 33 evaluable patients, unenriched for FolRα expression Starting Dose Best Overall Response (BOR) 4.3 mg/kg 5.2 mg/kg All Comers • 47.1% ORR in patients starting at the 5.2 mg/kg dose level Evaluable patients N=16 N=17 N=33

  12. Slide 12: Robust Anti-tumor Activity and Disease Control Demonstrated

    Robust Anti-tumor Activity and Disease Control Demonstrated STRO 002 Dose Expansion Responders experienced rapid tumor reduction or a steady deepening of response Change in Sum of Diameters for Target Lesions Over Time (N=33) Starting Dose, Q3W 4.3 mg/kg Change from baseline (%) 5.2 mg/kg Treatment

  13. Slide 13: Encouraging Response Rates and Preliminary Data on Durability

    Encouraging Response Rates and Preliminary Data on Durability STRO 002 Dose Expansion Interim data suggest initiating with 5.2 mg/kg followed by a dose adjustment Treatment Duration on Patients with at Least One Dose (N=43) Initial data show partial responses confirmed & Individual patients treated

  14. Slide 14: Platinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose Level

    Platinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose Level STRO 002 Dose Expansion Ongoing partial response with 72% reduction in tumor burden Initial diagnosis: Stage IV Lateral Abdominal Wall Axillary Lymph Node Inter-aortocaval LN External Iliac LN ovarian cancer, Jan 2020 3 Prior

  15. Slide 15: TPS Identified as Scoring Algorithm Appropriate for STRO-002

    TPS Identified as Scoring Algorithm Appropriate for STRO-002 STRO 002 Dose Expansion Exploratory analysis suggests TPS > 25% correlated with higher response ORR by TPS Expression Levels (Total Samples N=33) TPS TPS TPS TPS TPS Overall ≤ 25% > 25% > 50% > 75% Tumor Proportion Score (TPS) ORR 33.3% 12

  16. Slide 16: Emerging Safety Profile is Manageable – 85.5% of TEAEs were Grade 1-2

    Emerging Safety Profile is Manageable – 85.5% of TEAEs were Grade 1-2 STRO 002 Dose Expansion No new safety signals were observed, including the absence of keratopathy Most Common G3+ TEAEs (≥2 Subjects) by Dose 4.3 mg/Kg (N=23) 5.2 mg/Kg (N=20) Total (N=43) Asymptomatic neutropenia Grade 3 Grade 4

  17. Slide 17: Dose Expansion Interim Data Provide Initial Insights on Go-Forward Strategy

    Dose Expansion Interim Data Provide Initial Insights on Go-Forward Strategy STRO 002 Dose Expansion Emerging data inform potential starting dose and enrichment strategy Overall Efficacy Dose Response Biomarker Safety Profile Total of 11 confirmed PR (1) 47% ORR (8/17) in Interim data suggest TPS > N

  18. Slide 18: Progressing & Expanding the STRO-002 Franchise

    Progressing & Expanding the STRO-002 Franchise STRO 002 Additional clinical studies in ovarian & endometrial, and nonclinical work on other tumor types Ovarian Cancer Combo study with bevacizumab Trial is open and enrolling patients FPI March 2022 Dose-escalation cohort Dose-expansion cohort Registr

  19. Slide 19: STRO-003 and Emerging Research Portfolio

    STRO-003 and Emerging Research Portfolio 19 NON-CONFIDENTIAL

  20. Slide 20: STRO-003 is a Novel Optimized ROR1 ADC, Featuring TOPO-1 Inhibitors

    STRO 003 Our Innovative Design: STRO-003 is a Novel Optimized ROR1 ADC, Featuring TOPO-1 Inhibitors Linked with β-Glucuronidase Cleavable Linkers, DAR 8 STRO-003 is a single homogeneous antibody drug 1 conjugate (ADC) with a drug-antibody ratio (DAR) of 8, ROR1 targeting ROR1 tumor antigen 1 Targete

  21. Slide 21: STRO-003 Enables a Broad Clinical Development Strategy

    STRO 003 We Believe STRO-003 Enables a Broad Clinical Development Strategy Through Efficient Killing of Tumors with Low Level ROR1 Expression and Favorable Safety Profile Expansive indication space • Clinical validation of ROR1 in hematological indications and opportunity in broad solid tumors, incl

  22. Slide 22: STRO-003 Demonstrated Complete Regression of Human Patient-Derived NSCLC Xenografts

    STRO 003 STRO-003 Demonstrated Complete Regression of Human Patient-Derived NSCLC Xenografts Expressing Low and Heterogeneous ROR1 Antigen Levels in Preclinical Studies Human Patient-Derived NSCLC Xenografts CTG-0502 (ROR1 1+) CTG-2533 (ROR1 2+) CTG-2539 (ROR1 1-2+) CTG-0848 (ROR1 +1) CTG-1762 CTG-1

  23. Slide 23: STRO-003 Demonstrated a Wide Safety Window in Multiple Cross-Reactive Species

    STRO 003 legend STRO-003 Demonstrated a Wide Safety Window 1000 in Multiple Cross-Reactive Species retic (10^9/uL) STRO-003 was cross-reactive and well tolerated in rat at high doses 100 • No observed neutropenia, no elevation of liver enzymes at high doses (60 mg/kg) 10 STRO-003 was cross-reactive

  24. Slide 24: Drug Discovery Platform Enables Best-in-Class or First-in-Class Molecules

    Drug Discovery Platform Enables the Opportunity for Best-in-Class or First-in-Class Molecules Precise novel design to enhance efficacy and safety across multiple modalities and targets Conjugated Antibody Tumor Associated Antigen Targets ROR1 Tissue Factor Modality ADC iADC / ADC2 Bispecific ADC PTK

  25. Slide 25: New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC)

    New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC) Featuring dual drug conjugation technology with both cytotoxin and immune modulator Strategic iADC Collaboration June 27, 2022 • $90M upfront to develop iADCs for up to three targets • $422.5M in development, regulatory a

  26. Slide 26: STRO-001 CD74-Targeting ADC

    STRO-001 CD74-Targeting ADC 26 NON-CONFIDENTIAL

  27. Slide 27: Potential First-in-Class Molecule for Patients with NHL and MM

    Potential First-in-Class Molecule for Patients with NHL and MM STRO 001 Stable CD74 targeting ADC for hematological cancers designed to minimize bystander effects 1 CD74 STRO-001 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 2, targeting CD74: CD74 is expressed i

  28. Slide 28: STRO-001-BCM1 Study Design and Updates

    STRO-001-BCM1 Study Design and Updates STRO 001 Ongoing Phase 1 dose-escalation study in the U.S., and ex-U.S., outside of Greater China STRO-001-BCM1 Dose Escalation Study • Dose escalation ongoing at 5.0 mg/kg for NHL & 5.0 mg/kg for MM with sites open in the U.S., Israel, South Korea Cohort A R/R

  29. Slide 29: Encouraging Interim Treatment Duration and Responses

    Encouraging Interim Treatment Duration and Responses STRO 001 Partial responses in two DLBCL patients who had progressed on CAR-T Treatment Duration Responses to STRO-001 SD* Dose Best Doses Duration of Demographics and Level, Prior Therapies PR Diagnosis Responses Received Treatment Individual pati

  30. Slide 30: Financial Overview

    Financial Overview Well-capitalized through multiple funding sources $287.3M (1) Projected cash runway into in cash, cash equivalents & 1H 2024(1), marketable securities as of based on current business plans and September 30, 2022 assumptions ~1.5M shares Funding generated from our collaborators of

  31. Slide 31: Experienced Leadership Team

    Experienced Leadership Team William Newell, JD Trevor Hallam, PhD Ed Albini, MBA Linda Fitzpatrick Chief Executive Officer and President of Research and Chief Financial Officer Chief People and Member of the Board of Chief Scientific Officer Communications Officer Directors Jane Chung, RPh Shabbir A

Sutro Biopharma — Investor Presentation (November 2022) on 6ix